Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Expanded access study of satraplatin plus prednisone in patients with hormone refractory prostate cancer (HRPC) previously treated with unlimited cytotoxic chemotherapy regimen (SPERA)

Next Previous
X
Search
Trial Profile

Expanded access study of satraplatin plus prednisone in patients with hormone refractory prostate cancer (HRPC) previously treated with unlimited cytotoxic chemotherapy regimen (SPERA)

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 10 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Satraplatin (Primary) ; Prednisone
  • Indications Prostate cancer
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms SPERA

    • Most Recent Events

    • 08 May 2012 Actual patient number is 344 according to ClinicalTrials.gov.
    • 08 May 2012 Actual end date (Dec 2009) added as reported by ClinicalTrials.gov.
    • 08 May 2012 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top